Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
James Emmett Young, the Chief Financial Officer of TriSalus Life Sciences, Inc. (NASDAQ:TLSI), recently made significant stock purchases. According to a recent SEC filing, Young acquired 24,000 shares of the company’s common stock at a weighted average price of $5.40 per share, amounting to a total investment of $129,600. The purchase price sits above the current trading price of $4.89, though InvestingPro analysis suggests the stock may be slightly undervalued based on its Fair Value metrics. These shares were purchased through multiple transactions at prices ranging from $5.11 to $5.54. Additionally, Young received a grant of 12,500 restricted stock units and 75,000 employee stock options, both at no cost. The transactions reflect Young’s ongoing involvement and investment in the company, which maintains impressive gross profit margins of 87.1%. InvestingPro data reveals 8 additional key insights about TLSI’s financial health and market position.
In other recent news, TriSalus Life Sciences has reported a significant 59% annual revenue growth in 2024, driven largely by the TriNav Infusion System. The company’s full-year revenue for 2024 stood at approximately $29.4 million, with projections for continued momentum and over 50% growth expected for 2025. TriSalus also reported fourth-quarter earnings of approximately $8.3 million, a 44% rise compared to the same period in 2023.
In terms of leadership, the company has seen changes with the appointments of James Young as Chief Financial Officer, Dr. Richard Marshak as Chief Commercial Officer, and Jodi Devlin as Chief of Clinical Strategy and Operations. Additionally, TriSalus has launched the TriNav Large system, a medical device expected to address 30% more cases than its predecessor.
Analysts from Canaccord Genuity, Roth/MKM, and Northland have all given positive ratings for the company. Canaccord Genuity maintained a Buy rating with an adjusted price target to $11.00, while Roth/MKM and Northland initiated coverage with a Buy and an Outperform rating respectively. These ratings highlight the potential of TriSalus’s innovative TriNav catheter and Pressure Enabled Drug Delivery technology.
Finally, TriSalus is expanding its platform through the integration of the TriNav catheter with a proprietary TL-9 antagonist, currently undergoing phase 1 evaluation. The company has also secured an additional $10 million tranche from its existing debt agreement with OrbiMed, anticipated to provide sufficient liquidity through the end of the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.